ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-CCP antibodies"

  • Abstract Number: 2916 • 2017 ACR/ARHP Annual Meeting

    The Presence of a Large Number of Autoantibodies at Baseline Is Favourable for Early Treatment Response but Unfavourable for Drug-Free Remission in RA Patients

    Emma de Moel1, Veerle Derksen1, LA Trouw1, Holger Bang2, R.J. Goekoop3, I Speyer4, TWJ Huizinga1, CF Allaart1, REM Toes1 and Diane van der Woude5, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Orgentec Diagnostika GmbH, Mainz, Germany, 3Haga Hospital, The Hague, Netherlands, 4Haaglanden Medical Center, The Hague, Netherlands, 5Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: The autoantibody response of seropositive RA is very diverse and consists of various numbers of isotypes and antibodies to multiple post-translational modifications. It is…
  • Abstract Number: 239 • 2017 ACR/ARHP Annual Meeting

    Ultrasound Abnormalities Predict Arthritis Development in ACPA and/or RF Positive Arthralgia Patients

    Annelies Blanken1, Marian van Beers-Tas1, Marlies Meursinge Reynders1 and Dirkjan van Schaardenburg1,2, 1Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, 2Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands

    Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is important for controlling disease activity and preventing joint damage. Individuals positive for anticitrullinated protein antibodies (ACPA) and/or…
  • Abstract Number: 476 • 2017 ACR/ARHP Annual Meeting

    Novel Interaction between Anti-Citrulline Monoclonal Antibodies and Apoptotic Cells Is Mediated through Citrullinated Nuclear Antigens

    Katy A. Lloyd1, Peter Sahlström2, Johanna Steen1, Philip J. Titcombe3,4, Diana Zhou1, Christina Lundqvist5, Olov Ekwall6,7, Jimmy Ytterberg1, Johan Rönnelid8, Daniel L. Mueller3, Lars Klareskog1, Vivianne Malmström1 and Caroline Grönwall9, 1Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 2Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 3Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, 4Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Sweden, Sweden, 5Dept. of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden, 6Dept. of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy University of Gothenburg, Göteborg, Sweden, 7Dept of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden, 8Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden, 9Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) display broad cross-reactivities and target proteins including a-enolase, filaggrin, vimentin, fibrinogen, and histones. However, every monoclonal ACPA has a distinct…
  • Abstract Number: 477 • 2017 ACR/ARHP Annual Meeting

    Monoclonal ACPA-IgG Feature Extensive Fab Glycosylation

    Katy A. Lloyd1, Johanna Steen1, Philip J. Titcombe2,3, Khaled Amara4, Diana Zhou1, Lena Israelsson5, Susanna L. Lundström6, Daniel L. Mueller3, Lars Klareskog1, Vivianne Malmström1 and Caroline Grönwall7, 1Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 2Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Sweden, Sweden, 3Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, 4Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 5Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 6Dept. of Medical Biochemistry and Biophysics, Division of Physiological Chemistry, Karolinska Institutet, Stockholm, Sweden, 7Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Fab-glycosylation is found in ~15-25% serum IgG and while its exact consequence remains unknown, it may alter IgG functionality. Recent data revealed elevated Fab-glycosylation…
  • Abstract Number: 481 • 2017 ACR/ARHP Annual Meeting

    Immunocompetent Cells Expressing Citrullinated Proteins in Joint Synovium of Osteoarthritis and Rheumatoid Arthritis

    Kyoko Honne1, Masahiro Iwamoto2, Shunichiro Hanai1, Satoshi Machida3, Hitoshi Sekiya4, Reina Tsuda5, Tatsuhiko Ozawa5, Tadayoshi Karasawa6, Atsushi Muraguchi5, Masafumi Takahashi6, Hiroyuki Kishi5 and Seiji Minota7, 1Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, 2Deivision of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, 3Department of Orthopaedic Surgery, Orthopedics Clinic Medical Papas, Tochigi, Japan, 4Department of orthopedic surgery, Jichi Medical University, Shimotsuke, Japan, 5Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan, 6Division of Inflammation Research Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan, 7Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan

    Background/Purpose: Human monoclonal ACPA (Human-ACPA) is reported to strongly bind to synovium in RA patients [1]. The aims of our study were 1) To investigate…
  • Abstract Number: 483 • 2017 ACR/ARHP Annual Meeting

    Anti-Peptidylarginine Deiminase-4 Antibodies Are Present in the Sputum of RA Patients and Can Activate Peptidylarginine Deiminase-4 Enzyme Activity

    M. Kristen Demoruelle1, Hong Wang2, Ryan L. Davis2, A. Itzam Marin1, Jill M. Norris3, V. Michael Holers1, Kevin D. Deane1 and Erika Darrah2, 1Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 2Division of Rheumatology, The Johns Hopkins University, Baltimore, MD, 3Department of Epidemiology, Colorado School of Public Health, Aurora, CO

    Background/Purpose: Anti-peptidylarginine deiminase (PAD)-4 antibodies (Abs) are present in a portion of RA patients and associate with more severe joint disease, suggesting that they play…
  • Abstract Number: 1033 • 2017 ACR/ARHP Annual Meeting

    Burden of Illness in Patients with RA and Anti-Cyclic Citrullinated Peptide Positivity

    ML Paudel1, JP Swindle1, J McPheeters1, R Szymialis2 and K Price2, 1Optum, Inc., Eden Prairie, MN, 2Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: RA is often treated with a biologic DMARD (bDMARD), such as abatacept (ABA) or a TNF inhibitor (TNFi). Real-world data on how economic outcomes…
  • Abstract Number: 1034 • 2017 ACR/ARHP Annual Meeting

    Presence of Anti-Cyclic Citrullinated Peptide Antibodies Is Associated with Better Treatment Response to Abatacept but Not to TNF Inhibitors in Patients with RA: A Meta-Analysis

    E Alemao1, R Postema2, Y Elbez3, C Mamane4 and Axel Finckh5, 1Bristol-Myers Squibb, Princeton, NJ, 2Bristol-Myers Squibb, Uxbridge, United Kingdom, 3Excelya, Boulogne-Billancourt, France, 4Mapi, London, United Kingdom, 5University Hospital of Geneva, Geneva, Switzerland

    Background/Purpose: The association between anti-citrullinated protein antibody (ACPA) status and erosions, as well as response to TNF inhibitor (TNFi) treatment, has been explored.1,2 Results based…
  • Abstract Number: 1402 • 2017 ACR/ARHP Annual Meeting

    In RA, Becoming Seronegative over the 1st Year of DMARD Treatment Does Not Improve Chances of Drug-Free Remission in the Long-Term

    Emma de Moel1, Veerle Derksen1, LA Trouw1, Holger Bang2, Yvonne P. Goekoop-Ruiterman3, GM Steup-Beekman1,4, Tom W.J. Huizinga5, Cornelia F Allaart5, Rene E.M. Toes1 and Diane van der Woude6, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Orgentec Diagnostika GmbH, Mainz, Germany, 3Rheumatology, HAGA hospital, The Hague, Netherlands, 4Rheumatology, Haaglanden Medical Center, The Hague, Netherlands, 5Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 6Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Patients with RA harbor autoantibodies of various isotypes and directed against several post-translational modifications. Baseline seropositivity is a poor prognostic factor for sustained drug-free…
  • Abstract Number: 1220 • 2016 ACR/ARHP Annual Meeting

    Comparison of Healthcare Utilization of Patients with Rheumatoid Arthritis Who Are Anti-Cyclic Citrullinated Peptide Antibody Positive Versus Negative

    L Rosenblatt1, K Price1, Y Doleh1, A Szymialis1, M Eaddy2, A Ogbonnaya2, H-C Shih2 and L Lamerato3, 1Bristol-Myers Squibb, Princeton, NJ, 2Xcenda, LLC, Palm Harbor, FL, 3Henry Ford Health System, Detroit, MI

    Background/Purpose: Anti-cyclic citrullinated peptide (CCP) antibody is a marker used in the diagnosis of RA, and it may be useful in identifying patients who are…
  • Abstract Number: 1226 • 2016 ACR/ARHP Annual Meeting

    Evaluation of the Association Between C-Reactive Protein and Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: Analysis of Two Clinical Practice Data Sets

    E Alemao1, Z Guo1, L Burns1, M Frits2, Jonathan Coblyn2, Michael Weinblatt2 and NA Shadick2, 1Bristol-Myers Squibb, Princeton, NJ, 2Brigham and Women’s Hospital, Boston, MA

    Background/Purpose: The association between inflammatory markers such as CRP or ESR and joint damage has been widely established in RA. Autoantibodies such as RF and…
  • Abstract Number: 1483 • 2016 ACR/ARHP Annual Meeting

    Elevated Anti-Cyclic Citrullinated Peptide Antibody Titer Is Associated with Increased Cardiovascular Risk

    Sarah A. Fantus1, Melissa R. Bussey2, Rochella A. Ostrowski3, Andrew Heisler1 and Kyle Carey4, 1Internal Medicine, Loyola University Medical Center, Maywood, IL, 2Division of Allergy, Immunology, and Rheumatology, Loyola University Medical Center, Maywood, IL, 3Rheumatology, Loyola University Medical Center, Maywood, IL, 4Clinical Research Office, Loyola University Chicago, Maywood, IL

    Background/Purpose: Rheumatoid arthritits (RA) patients have an increased risk of mortality from cardiovascular (CV) disease.  Proposed adaptation of CV risk score models in RA patients…
  • Abstract Number: 1976 • 2016 ACR/ARHP Annual Meeting

    Ultrasound Inflammation in Patients Presenting with Arthralgia Is Associated with Developing Arthritis

    Myrthe van der Ven1, Marjolein Van der Veer-Meerkerk1, David F. Ten Cate2, Nigara Rasappu3, Marc R. Kok4, Dora Csakvari5, Johanna M.W. Hazes2, Andreas H. Gerards6 and Jolanda J. Luime3, 1Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, 2Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, 3Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, 4Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 5Rheumatology, Erasmus University Medical Centre, ROTTERDAM, Netherlands, 6Rheumatology, Vlietland Hospital, Schiedam, Netherlands

    Background/Purpose: To further decrease the burden of RA we need to identify patients early, preferably in absence of clinical apparent synovitis. Recent studies in US…
  • Abstract Number: 2117 • 2016 ACR/ARHP Annual Meeting

    B Cell Phenotype and in Vitro Function in Patients with Rheumatoid Arthritis Developing Low Serum Immunoglobulins after Multiple Cycles of Rituximab

    Geraldine Cambridge1, Rita A. Moura2, Venkat Reddy3 and Maria J. Leandro1, 1Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 2Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Lisbon, Portugal, 3Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Repeat treatment with rituximab (RTX) predisposes some patients with rheumatoid arthritis (RA) to develop low levels of serum immunoglobulins (Igs). Understanding B cell function…
  • Abstract Number: 2416 • 2016 ACR/ARHP Annual Meeting

    Antibodies to Citrullinated Peptides in Patients with Juvenile Idiopathic Arthritis and Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype

    Hannah Peckham1, Lauren Bourke1, Anna Radziszewska1, Maria J. Leandro2, Debajit Sen1, Geraldine Cambridge2 and Yiannis Ioannou1, 1Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 2Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom

    Background/Purpose: Rheumatoid factor (RF) positive polyarticular JIA (RF+ve pJIA) frequently progresses into adulthood with a clinical phenotype that ressembles rheumatoid arthritis (RA). Antibodies to cyclic…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology